Back

Health-related quality of life in patients with symptomatic transthyretin amyloid cardiomyopathy treated with acoramidis: an EQ-5D analysis from the ATTRibute-CM study

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - clinical 3 Clinical HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Peter Van Der Meer

University Medical Centre Groningen, Groningen (Netherlands (The))

7 More presentations in this session

Presentation thumbnail
Temporal trends and clinical characteristics of variant versus wild-type transthyretin amyloid cardiomyopathy in Asian population: the Korean nationwide cohort study
Professor J. Youn (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Impact of the non-invasive diagnostic algorithm on clinical presentation and prognosis in a nationwide multicentric light-chain and transthyretin-related cardiac amyloidosis cohort
Doctor G. Tini Melato (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Validation of two clinical scores for transthyretin amyloid cardiomyopathy in a mediterranean cohort of patients at risk
Doctor M. Llevadot Sesmilo (Badalona, ES)
Abstract Slides Video
Presentation thumbnail
Multimodality imaging to improve detection and prognostication of right ventricular involvement in cardiac sarcoidosis
Doctor J. Okafor (London, GB)
Abstract Slides Video
Presentation thumbnail
Improved health-related quality of life in acoramidis-treated patients with ATTR-CM, demonstrated by improvements in KCCQ scores
Professor M. Fontana (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease - clinical 3

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Effect of acoramidis on functional capacity and quality of life in patients with variant ATTR-CM: results from ATTRibute-CM
thumbnail
Congress Presentation
Improved health-related quality of life in acoramidis-treated patients with ATTR-CM, demonstrated by improvements in KCCQ scores
thumbnail
Congress Presentation
Tafamidis and patient-reported outcomes in ATTR cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources